RTP Mobile Logo
Lung Cancer Update Think Tank, Issue 1, 2011
Released December 2011

Roundtable participants include Drs Chandra P Belani, John Heymach, Corey J Langer, Rogerio C Lilenbaum, Thomas J Lynch Jr, Vincent A Miller, Lecia V Sequist and Mark A Socinski. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Lung cancer is increasingly being recognized as a heterogeneous group of tumors. Not long ago, it was clinically sufficient to make a differentiation between small cell lung cancer and non-small cell lung cancer (NSCLC). Published results from recent trials have led to the approval of 3 different agents for NSCLC in the maintenance setting, with only 1 of these being for the broad population of patients with NSCLC. Individualized treatment decisions are increasingly driven by genetic biomarkers in addition to histological subtype and patient-specific characteristics. Determining which treatment approach is most appropriate in a given case requires careful consideration of patient characteristics, biomarkers and available health-system resources. Oncology clinicians must possess a clear understanding of the benefits and risks of each of the various available options and how best to integrate the emerging data and agents into the therapeutic algorithm. To bridge the gap between research and patient care, this activity is designed to expose oncology clinicians to the available peer-reviewed evidence and expert perspectives that can be translated into strategies for optimal patient care.

    LEARNING OBJECTIVES

    • Apply the results of emerging clinical research to the current and future treatment of NSCLC.
    • Identify patients with metastatic NSCLC who may experience incremental benefit from maintenance biologic therapy and/or chemotherapy.
    • Use biomarkers, clinical characteristics and tumor histology to select individualized front-line treatment approaches for patients with NSCLC.
    • Educate appropriately selected patients about the benefits and risks of combination chemotherapy with bevacizumab or cetuximab.
    • Recognize the effects of NSCLC tumor-specific mutations on prognosis and/or response to treatment with EGFR inhibitors.
    • Recall the scientific rationale for investigational agents demonstrating promising activity in NSCLC, and distinguish how they may enhance existing therapeutic standards.
    • Formulate an evidence-based treatment approach to adjuvant chemotherapy for NSCLC that recognizes the toxicities of different doublet regimens.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in lung cancer, and counsel appropriately selected patients about study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should review the CME information, listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BelaniAdvisory Committee: Genentech BioOncology, Lilly USA LLC, Pfizer Inc; Consulting Agreements: Genentech BioOncology, Lilly USA LLC. Dr HeymachConsulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc; Paid Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Pfizer Inc. Dr LangerAdvisory Committee and Consulting Agreements: Allos Therapeutics, ARIAD Pharmaceuticals Inc, Bayer HealthCare Pharmaceuticals, Biodesix, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, OSI Oncology, Pfizer Inc; Data and Safety Monitoring Committee: Amgen Inc. Dr LilenbaumConsulting Agreements: Celgene Corporation, Genentech BioOncology. Dr LynchBoard of Directors: Infinity Pharmaceuticals Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, SuperGen Inc; Stock Ownership: Biogen Idec, Infinity Pharmaceuticals Inc. Dr MillerAdvisory Committee: Cylene Pharmaceuticals, Sanofi; Consulting Agreements: Allos Therapeutics, ArQule, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly USA LLC, Nereus Pharmaceuticals Inc, Pfizer Inc; Honoraria: ArQule, Nereus Pharmaceuticals Inc; Paid Research: Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech BioOncology, Pfizer Inc. Dr SequistAdvisory Committee: GlaxoSmithKline; Paid Research: Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech BioOncology, Lilly USA LLC, Merrimack Pharmaceuticals. Dr SocinskiPaid Research: Celgene Corporation, Genentech BioOncology, Lilly USA LLC, Pfizer Inc, Synta Pharmaceuticals Corp; Speakers Bureau: Genentech BioOncology, Lilly USA LLC.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Sanofi, Seattle Genetics and Teva Pharmaceuticals.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Genentech BioOncology & OSI Oncology and Lilly USA LLC.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2011
    Expiration date: December 2012

Acknowledge and close

Listen to Audio Excerpts:
Lung Cancer Update Think Tank, Issue 1, 2011
Released December 2011

Roundtable participants include Drs Chandra P Belani, John Heymach, Corey J Langer, Rogerio C Lilenbaum, Thomas J Lynch Jr, Vincent A Miller, Lecia V Sequist and Mark A Socinski. (Text and Audio Content)

Text Excerpt: